Pharmaceutical company Pfizer announced Tuesday that a new experimental drug combination showed promising results in treating breast cancer patients, demonstrating a 40% reduction in the risk of disease progression or death.
The treatment pairs Pfizer’s investigational drug atirmociclib with fulvestrant, an established hormone therapy. Researchers conducted the mid-stage clinical trial on patients whose breast cancer had metastasized and who had undergone previous treatments.
The study compared this new drug combination against standard treatment options including fulvestrant alone or a combination of everolimus and exemestane, which represents a commonly prescribed targeted therapy approach for postmenopausal women diagnosed with the most prevalent form of breast cancer.
Trial participants included patients whose cancer had returned quickly following treatment with CDK4/6 inhibitors, a patient population that typically presents greater treatment challenges. More than 90% of study participants began taking atirmociclib within three months after discontinuing their previous cancer medication.
According to Pfizer, the experimental treatment demonstrated a tolerable safety profile, with only 6.4% of patients discontinuing the therapy due to adverse effects. The company noted that overall survival statistics, which serve as a secondary endpoint, remain preliminary and insufficient for drawing definitive conclusions at this time.
The positive trial results will support Pfizer’s plans to evaluate atirmociclib in earlier stages of breast cancer treatment, including first-line therapy and early-stage disease, where extended disease management could benefit a larger patient population.
Atirmociclib functions as an oral medication that specifically targets CDK4, a protein involved in cell cycle regulation that promotes tumor development. Pfizer has already initiated a comprehensive late-stage clinical study examining the drug’s effectiveness in patients recently diagnosed with metastatic breast cancer.
